
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

Forty Seven, a spinout from Stanford University, has had a busy few days – first announcing that it had filed …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

